|59.32||+1.50||+2.59%||Vol 325.07K||1Y Perf -18.16%|
|May 13th, 2022 16:00 DELAYED|
|- -%||- -|
|Target Price||69.00||Analyst Rating||Hold 2.86|
|Potential %||16.32||Finscreener Ranking||★ 40.00|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★ 45.98|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★+ 48.46|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||19.31||Earnings Rating||Sell|
|Market Cap||4.93B||Earnings Date||27th Apr 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||0.68|
|EPS Growth Next 5 Years %||9.60|
|Avg. Weekly Volume||449.99K|
|Avg. Monthly Volume||472.15K|
|Avg. Quarterly Volume||503.34K|
Integra LifeSciences Holdings Corporation (NASDAQ: IART) stock closed at 59.32 per share at the end of the most recent trading day (a 2.59% change compared to the prior day closing price) with a volume of 325.07K shares and market capitalization of 4.93B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 3700 people. Integra LifeSciences Holdings Corporation CEO is Peter J. Arduini.
The one-year performance of Integra LifeSciences Holdings Corporation stock is -18.16%, while year-to-date (YTD) performance is -11.45%. IART stock has a five-year performance of 27.9%. Its 52-week range is between 55.16 and 76.7, which gives IART stock a 52-week price range ratio of 19.31%
Integra LifeSciences Holdings Corporation currently has a PE ratio of 32.10, a price-to-book (PB) ratio of 3.04, a price-to-sale (PS) ratio of 3.01, a price to cashflow ratio of 17.50, a PEG ratio of 2.32, a ROA of 4.35%, a ROC of 5.88% and a ROE of 10.24%. The company’s profit margin is 10.05%, its EBITDA margin is 22.80%, and its revenue ttm is $1.56 Billion , which makes it $18.75 revenue per share.
Of the last four earnings reports from Integra LifeSciences Holdings Corporation, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.68 for the next earnings report. Integra LifeSciences Holdings Corporation’s next earnings report date is -.
The consensus rating of Wall Street analysts for Integra LifeSciences Holdings Corporation is Hold (2.86), with a target price of $69, which is +16.32% compared to the current price. The earnings rating for Integra LifeSciences Holdings Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Integra LifeSciences Holdings Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Integra LifeSciences Holdings Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 7.02, ATR14 : 2.02, CCI20 : -67.90, Chaikin Money Flow : -0.10, MACD : -1.56, Money Flow Index : 37.26, ROC : -4.46, RSI : 45.13, STOCH (14,3) : 43.11, STOCH RSI : 1.00, UO : 47.24, Williams %R : -56.89), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Integra LifeSciences Holdings Corporation in the last 12-months were: Glenn G. Coleman (Sold 10 543 shares of value $730 289 ), Jeffrey A. Mosebrook (Sold 700 shares of value $49 616 ), Lisa Evoli (Sold 1 254 shares of value $84 056 ), Michael McBreen (Sold 7 450 shares of value $531 878 ), Peter J. Arduini (Option Excercise at a value of $2 472 901), Peter J. Arduini (Sold 118 434 shares of value $8 987 121 ), Raymond G. Murphy (Sold 1 253 shares of value $84 220 )
Sat, 05 Mar 2022 09:06 GMT Integra Lifesciences (IART) Gets a Hold Rating from J.P. Morgan- TipRanks. All rights reserved.
Wed, 12 Jan 2022 00:05 GMT Integra Lifesciences (IART) Gets a Hold Rating from BTIG- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.